Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s (Open Orphan PLC (AIM:ORPH, OTC:OPORF), Open Orphan PLC (AIM:ORPH, OTC:OPORF)) Cathal Friel talks about the business opportunities after revealing data showing their SARS-CoV-2 human challenge studies are safe in healthy young adults.
The firm has announced the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust.
He says no serious adverse events or serious symptoms were shown, demonstrating that a COVID-19 human challenge study is safe in healthy young adults. The results, he says, have provided invaluable insights into COVID-19 disease progression.